<span style="display: block; margin-top: 60px;"> Trurapi<sup>®<span style="color: black;">▼</span></sup><span style="font-size: 0.6em; display: block; margin: 5px 0;">(insulin aspart 100 units/mL)</span></span>
The first rapid acting insulin biosimilar of NovoRapid® approved in the UK and EU1
Available to prescribe in England, Scotland and Wales.
30% lower NHS list price vs. NovoRapid2
1:1 initial unit dosing - available in the SoloStar pen and cartridges1, 3-4
*When transferring from other insulin products, dose adjustment of Trurapi® or basal insulin may be needed. Insulin aspart has a faster onset and shorter duration of action than soluble human insulin. Close glucose monitoring during transfer and initial weeks is recommended.1
Similar PK/PD profile (T1DM), efficacy, safety and tolerability (T1DM and T2DM)3-4
Diabetes Stories
Learn from other payors, consultants and diabetes specialist nurses how they adopted a rapid acting insulin biosimilar in their region.
These videos are related to HCPs sharing their experiences with a different rapid acting insulin biosimilar.
Dr Duncan Browne
Consultant Endocrinologist and Researcher Royal Cornwall Hospitals NHS Foundation Trust
Amanda Veall
Diabetes Specialist Nurse Cornwall Partnership NHS Foundation Trust
Marcus Jones
Formulary Pharmacist Gloucestershire Hospitals NHS Foundation Trust
Find useful resources such as formulary FAQ, leave pieces and videos for payors and healthcare professionals to support a positive rapid acting insulin biosimilar adoption
Have you got any questions?
Leave your contact details with us and your area representative will get back to you shortly.
Abbreviations:
EU, European Union; FAQ, frequently asked questions; NHS, National Health Service; PD, pharmacodynamic; PK, pharmacokinetic; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UK, United Kingdom.
References:
- Trurapi SmPC (April 2021)
- Data on File, MAT-GB-2101599 (v1.0) April 2021
- Kapitza C, et al. Diabetes Technol Ther. 2020;22(4):278–284.
- Garg SK, et al. Diabetes Technol Ther. 2020;22(2):85–95.